Corporate information as at 16 June 2017

ASX 300 company

ASX code: SPL

US OTCQX code: SPHRY

Share price: A$0.75

Market capitalisation: ~A$275M

Shares outstanding: 369.1M

Est. Cash (at 30 Jun 2017): >A$60M

Average ASX daily volume: ~400K shares

Company contact information:

Address: 4-6 Southampton Cres, Abbotsford 3067, AUSTRALIA

Phone: (03) 8532 2700

Key contacts:

Jackie Fairley, CEO
+61 3 8532 2704
jackie.fairley@starpharma.com

Nigel Baade, CFO & Company Secretary
+61 3 8532 2704
nigel.baade@starpharma.com

Rebecca Wilson, Media & IR
WE Buchan
+61 3 8866 1200
rwilson@buchanwe.com.au

Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is a global biopharmaceutical company based in Australia with established commercial partnerships and products launched, or nearing commercial launch, across the pharmaceutical and sexual health sectors based on a proprietary dendrimer platform.

Investment Proposition

- **Unique proprietary dendrimer technology platform**
- **Product portfolio targeting large, high value and diversified markets**
- **Proven track record of commercialisation**
  - **VivaGel® condom in-market (Australia & North America)**
  - **VivaGel® BV – treatment product awaiting launch and prevention product in late stage development**
  - **Added significant value to Priostar® (Agrochemicals) portfolio, recently sold to Agrium Inc. for A$35M**
- **Successful partnership strategy delivering results with several licencing deals and commercial arrangements in place, accelerating path to market and managing investment risk**
- **Well-funded, with existing cash reserves of more than A$60m**



VivaGel® condom: World's first and only antiviral Condom

- Condom lubricant contains VivaGel® which has been proven in laboratory studies to inactivate up to 99.9% of HIV, HSV and HPV, which are viruses that cause sexually transmitted infections (STIs)
- VivaGel® condom is available in Australia and Canada under Ansell's Lifestyles® Dual Protect™ brand
- Licensed to Ansell, Okamoto (Japan), Koushan Pharmed (Iran) and Sky & Land (China - for the Government sector – annual government requirement: ~3 billion condoms)
- Advanced regulatory review in other markets

VivaGel® BV: breakthrough products for bacterial vaginosis (BV)

VivaGel® BV formulated as a water-based gel and delivered vaginally – already approved in Europe for treatment and symptomatic relief of bacterial vaginosis (BV) with Phase 3 clinical trials recently completed for the prevention of recurrent BV. Bacterial Vaginosis is the most common vaginal infection globally affecting around 30% of women in the US. **Extensive partnering discussions are underway in several regions and a global healthcare bank was recently engaged to support global negotiations.**

VivaGel® BV - treatment and symptomatic relief

- An acute use product, in an estimated market valued at >US$750M globally
- Licensed to Aspen in Australia and New Zealand – 2017 product launch
- EU approval received – regulatory processes leveraging EU approval underway in multiple regions and advanced commercial discussions with global partners
- NDA submission in preparation; Qualified Infectious Disease Product (QIDP) designation and Fast Track status granted by the US FDA

Benefits of VivaGel® BV

- Rapid relief and resolution
- Non-antibiotic
- Not systemically absorbed
- Excellent tolerability
- Selective antimicrobial effect

VivaGel® BV – for prevention of recurrence

- Chronic use product, in an estimated market valued at >US$1B globally
- Majority of BV sufferers experience recurrence – this is an unmet need with no currently approved products
- Phase 3 trials completed; Results expected in late Q2/early Q3 CY17
- Special Protocol Assessment (SPA) granted by the US FDA (reduces regulatory risk for the clinical program)
- NDA submission in preparation; Qualified Infectious Disease Product (QIDP) designation and Fast Track status granted by the US FDA

DEP® drug delivery – revolutionary platform

Starpharma's novel DEP® platform has broad commercial applicability in drug delivery by enhancing the performance and reducing toxicity of existing drugs as well as extending the patent life of existing or new drugs.

Example of DEP® license - AstraZeneca

- First DEP® candidate receipts est. US$450M (US$126M + royalties)
- Subsequent DEP® candidates US$93M + royalties
- Tiered royalties on Net Sales on the resultant AstraZeneca DEP® products
- AstraZeneca funds all development and commercialisation costs

Partnered DEP® programs (partner funded)

Starpharma's partnership with AstraZeneca includes a multiproduct DEP® licence which currently involves the development and commercialisation of two novel AstraZeneca oncology compounds with potential to add more. AstraZeneca recently paid Starpharma a US$2M milestone payment for its first DEP® candidate, which was triggered by reaching the final preclinical stage, prior to advancing to clinical trials. During 2016, AstraZeneca also initiated another new DEP® drug delivery program for a product in its portfolio - further validation of the value of Starpharma's DEP® platform and its broad application.

"SPL estimates that each product successfully commercialised under this agreement could be worth around US$450m to Starpharma and, depending on the range of indications and degree of commercial success in the market, potentially significantly more." - Jackie Fairley Starpharma CEO

"Achievement of this important development milestone is indicative of the success we have seen in our DEP® program in partnership with Starpharma. It is a highly productive collaboration and the DEP® technology has enabled us to advance a very exciting novel oncology agent towards the clinic. We're continuing to investigate the potential of DEP® more broadly across molecules within our oncology portfolio." - Dr Susan Galbraith, SVP, Head of the Oncology Innovative Medicines Unit at AstraZeneca

Starpharma has also signed two Targeted DEP® partnerships with world leading antibody-drug conjugate companies.

Benefits of DEP®

- Improved efficacy
- Reduced toxicity
- Improved pharmacokinetics
- Improved solubility
- Patent life extension

Internal DEP® programs

- DEP® docetaxel: enhanced version of anti-cancer drug Taxotere® - modified to reduce side effects such as hair loss and white blood cell toxicity while enhancing efficacy. Encouraging efficacy signals in a range of cancers emerging from the current Phase 1 trial, and will soon enter Phase 2.
- DEP® cabazitaxel: detergent free version of leading cancer drug Jevtana®. Significantly outperformed Jevtana® in a human breast cancer model with respect to both level and duration of anticancer activity and survival, and with superior safety. Will enter Phase 1 in 2H CY2017.
- DEP® irinotecan: improved version of irinotecan has demonstrated significantly better anti-tumour activity and increased survival compared with irinotecan in a variety of human colon cancer models.
- Targeted DEP®: Starpharma's novel antibody-targeted DEP® conjugate resulted in complete tumour regression and 100% survival in an ovarian cancer model.

Starpharma's Partners

AstraZeneca · aspen · Ansell · okamoto · SKY & LAND · Koushan Pharmed